Download PDF
Thromb Haemost 2009; 101(01): 5-6
DOI: 10.1160/TH08-11-0763
Editorial Focus
Schattauer GmbH

VTE recurrence in patients with inherited deficiencies of natural anticoagulants

Francesco Dentali
1   Department of Cinical Medicine, Insubria University, Varese, Italy
,
Monica Gianni
2   Department of Cardiology, Hospital of Tradate, Tradate, Italy
› Author Affiliations
Further Information

Publication History

Received: 24 November 2008

Accepted: 24 November 2008

Publication Date:
23 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Prandoni P, Lensing AWA, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
    CrossrefPubMedGoogle Scholar
  • 2 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism—A population-based cohort study. Arch Intern Med 2000; 160: 761-768.
    CrossrefPubMedGoogle Scholar
  • 3 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (IS-COAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
    CrossrefPubMedGoogle Scholar
  • 4 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
    CrossrefPubMedGoogle Scholar
  • 5 Levine MN, Hirsh J, Gent M. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-611.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Kearon C, Kahn S, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2008; 133: 454S-545S.
    CrossrefPubMedGoogle Scholar
  • 7 Palareti G, Cosmi B, Legnani C. et al; PROLONG Investigators.. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
    CrossrefPubMedGoogle Scholar
  • 8 Prandoni P, Lensing AW, Prins MH. et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-960.
    CrossrefPubMedGoogle Scholar
  • 9 Eichinger S, Weltermann A, Minar E. et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164: 92-96.
    CrossrefPubMedGoogle Scholar
  • 10 McRae S, Tran H, Schulman S. et al. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368: 371-378.
    CrossrefPubMedGoogle Scholar
  • 11 Ho WK, Hankey GJ, Quinlan DJ. et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
    CrossrefPubMedGoogle Scholar
  • 12 De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-3544.
    PubMedGoogle Scholar
  • 13 Martinelli I, Mannucci PM, De Stefano V. et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
    PubMedGoogle Scholar
  • 14 Baglin T, Luddington R, Brown K. et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
    CrossrefPubMedGoogle Scholar
  • 15 Christiansen SC, Cannegieter S, Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-2361.
    CrossrefPubMedGoogle Scholar
  • 16 Brouwer JL, Lijfering LM, ten Kate MI. et al. High long term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101: 93-99.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Brouwer JL, Veeger NJ, Schaaf W. et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005; 128: 703-710.
    CrossrefPubMedGoogle Scholar
  • 18 Lensen RP, Rosendaal FR, Koster T. et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996; 88: 4205-4208.
    PubMedGoogle Scholar